NEW YORK (GenomeWeb News) – Madison, Wis.-based Cellular Dynamics and Sittingbourne, England-based VivoMedica today said that they have launched a consortium to validate a human cell model and analysis system, based on the firms' technologies, for preclinical cardiotoxicity testing of drug candidates.

The firms said the consortium is being launched this week in France at the Safety Pharmacology Society 9th Annual Meeting. The firms hope to enlist pharmaceutical companies in validating the human cardiac model.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.

Jun
26
Sponsored by
Lexogen

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.